1. Home
  2. MREO

as of 11-16-2026 3:26pm EST

$0.30
$0.00
-0.72%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Founded: 2015 Country:
United Kingdom
United Kingdom
Employees: N/A City: LONDON
Market Cap: 50.3M IPO Year: 2017
Target Price: $1.96 AVG Volume (30 days): 632.5K
Analyst Decision: Buy Number of Analysts: 8
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.02 EPS Growth: 16.67
52 Week Low/High: $0.20 - $2.37 Next Earning Date: 11-09-2026
Revenue: $500,000 Revenue Growth: N/A
Revenue Growth (this year): 59.51% Revenue Growth (next year): 2326.81%
P/E Ratio: -15.32 Index: N/A
Free Cash Flow: -30991000.0 FCF Growth: N/A

AI-Powered MREO Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

sell
Model Precision: 26.32%
26.32%
AI Precision

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 9, 2026 · 100% conf.

AI Prediction SELL

1D

+1.29%

$0.29

Act: +1.69%

5D

-5.24%

$0.27

20D

+9.37%

$0.32

Price: $0.29 Prob +5D: 0% AUC: 1.000
0001193125-26-452716

EX-99.1

2 mreo-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

Mereo BioPharma Reports Third Quarter 2026 Financial Results

Ongoing regulatory interactions in collaboration with Ultragenyx on potential path forward for setrusumab in osteogenesis imperfecta (OI)

Ongoing FDA interactions in collaboration with Sentynl Therapeutics to refine Phase 3 trial design for alvelestat in alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD)

Cash and cash equivalents of $26.1 million at September 30, 2026, expected to fund operations into late-2027

London, November 9, 2026 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the third quarter ended September 30, 2026, and provided an update on its late-stage programs.

“During the third quarter, we have made meaningful progress on our two core programs, setrusumab and alvelestat. These developments have the potential to set the stage for a transformational 2027 for Mereo, our shareholders and the patients we aim to serve,” said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma. In collaboration with our partner Ultragenyx, we are continuing to work closely with the regulators, to determine the necessary data to support a regulatory submission for setrusumab in OI and if there is a potential path forward. We believe that the data from post-hoc fracture analyses presented at the recent American Society for Bone and Mineral Research (ASBMR) Annual Meeting further support setrusumab’s potential to provide meaningful benefit, particularly in pediatric, higher fracturing patients. We are also advancing our regulatory interactions on alvelestat for AATD-LD alongside Sentynl Therapeutics to streamline the Phase 3 design and are working to be in a position to initiate the Phase 3 study in early 2027. We continue to expect that our current cash position, which totaled $26.1 million as of September 30, will provide runway into late-2027, exclusive of the potential $40 million in upfront and R&D payments associated with the exercise of the alvelestat option by Sentynl and any other milestone payments which would further extend the runway.”

Recent Developments and Anticipated Milestones

Setrusumab (UX143) for osteogenesis imperfecta (OI)

• Following the results of the Orbit and Cosmic Phase 3 studies of setrusumab in OI, reported in December 2025, Mereo and its partner, Ultragenyx Pharmaceutical, Inc. (Ultragenyx), have engaged with regulatory agencies to determine a potential path forward for setrusumab in pediatric OI patients. These interactions have focused on understanding the necessary data to support a regulatory filing and if there is a potential path forward.

• Data from pre- and post-hoc analyses from both the Orbit and Cosmic studies were presented at the 2026 ASBMR Annual Meeting held in October. These data included baseline characteristics, as well as annual fracture rate (AFR) analyses in certain patient subgroups. These pre- and post-hoc analyses on total fractures in patients enrolled with at least 3 fractures in the prior 2 years showed a meaningful benefit on fractures, bone mineral density and other endpoints in the two Phase 3 studies.

Alvelestat (MPH-966) for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD)

• In August, Mereo announced an option and license agreement with Sentynl Therapeutics, Inc. (Sentynl), a wholly owned subsidiary of Zydus Lifesciences Limited, which granted Sentynl the right to acquire a license for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD.

• Should Sentynl exercise its option during the short option period, Mereo would receive $40 million in upfront and R&D payments which would provide funding for the Phase 3 study. Mereo would also be eligible to receive up to $435 million in regulatory and commercial milestones, as well as double-digit tiered royalties on U.S. net sales of alvelestat. Mereo will lead the global Phase 3 study and all regulatory interactions until study completion.

• Since signing the option and license agreement, the companies have been collaborating to streamline the design of the planned Phase 3 study. In parallel, Mereo has been working to be in a position to initiate the Phase 3 study in early 2027.

• Based on ongoing FDA interactions, Mereo expects to provide an update before the end of the year.

Vantictumab (OMP18R5) for autosomal dominant osteopetrosis type 2 (ADO2)

• āshibio, Inc. (āshibio), Mereo’s development and commercial partner for vantictumab, reported clinical biomarker data from a legacy study of vantictumab in patients with cancer at the 2026 ASBMR Annual Meeting.

o These data showed that low doses of vantictumab (0.5-5mg/kg) administered once weekly or once every two or three weeks, increased osteoclast activity without inhibiting osteoblast activity at these low doses.

o Results were consis

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 11, 2026 · 100% conf.

AI Prediction SELL

1D

+1.23%

$0.31

Act: +0.62%

5D

-5.24%

$0.29

20D

+9.37%

$0.34

Price: $0.31 Prob +5D: 0% AUC: 1.000
0001193125-26-343519

EX-99.1

2 mreo-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights

Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); further updates expected by year-end 2026

Cash and cash equivalents of $30.1 million at June 30, 2026, now expected to fund operations into late-2027

London, August 11, 2026 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the second quarter ended June 30, 2026, and provided an update on recent corporate highlights.

The Company is also updating its previous cash runway guidance. As of June 30, 2026, cash and cash equivalents were approximately $30 million, which are expected to fund operations into late-2027.

“The partnership with Sentynl Therapeutics which we announced earlier today marks a significant milestone for our alvelestat program and for the Company as a whole. We are now working together to refine the design of the global Phase 3 study for our potential first-in-class oral therapy for AATD-LD and look forward to a continued close collaboration during the short option period. Assuming exercise of the license option by Sentynl, we plan to initiate the Phase 3 trial in early 2027,” said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma. “Additionally, alongside our partner Ultragenyx, we have had initial regulatory interactions on setrusumab with the FDA and the MHRA and we expect to be in a position to provide an update on the potential path forward by the end of this year. We finished the quarter with approximately $30 million in cash. Thanks to our careful expense management, we now expect that this cash will provide runway into late-2027, exclusive of the potential $40 million in upfront and R&D payments that we are eligible to receive on exercise of the alvelestat option by Sentynl.”

Second Quarter 2026 Highlights, Recent Developments, and Anticipated Milestones

Setrusumab (UX143)

• The Orbit and the Cosmic Phase 3 studies did not achieve statistical significance against the primary endpoints of reduction in annualized clinical fracture rate, however, both achieved high statistical significance against the key secondary endpoint of improvement in bone mineral density, as well as reductions in vertebral fractures and improvements in patient reported outcomes (PROs) associated with disease severity, pain / discomfort and daily activities, with these PRO improvements achieving statistical significance in the Orbit study. Setrusumab also achieved meaningful reductions in fractures in certain bones and in patients with higher fracture frequencies. Both studies demonstrated a safety profile consistent with that observed in previous trials.

• Mereo and its partner, Ultragenyx Pharmaceutical, Inc. (“Ultragenyx”), are engaged with regulatory agencies to determine a potential path forward for setrusumab in pediatric OI patients and, to-date, have held discussions with the regulators in the U.S. and the U.K. The FDA indicated openness to considering alternative approaches to fracture analysis, with additional conversations needed to further define what additional clinical data would be needed to support a potential BLA. In recent communications with the MHRA, they encouraged further dialogue on any future development proposal, and we plan to have further interactions following the FDA discussions.

Alvelestat (MPH-966)

• Mereo recently announced an option and license agreement with Sentynl Therapeutics, Inc. (Sentynl), a wholly owned subsidiary of Zydus Lifesciences Limited. Sentynl has the right to acquire a license for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD.

o Sentynl is a California-based, commercial-stage biopharmaceutical company with three currently approved products for rare diseases.

o Under the agreement, the companies will collaborate to refine the design of the planned global Phase 3 trial of alvelestat and to advance the manufacturing during the short option period.

• Mereo will receive a non-refundable option fee and, on option exercise, would also be eligible to receive $40 million in upfront and R&D payments, up to $435 million in regulatory and commercial milestone payments, as well as double-digit tiered royalties on U.S. net sales of alvelestat.

• Mereo will lead the global Phase 3 study and regulatory interactions until study completion and will retain rest-of-world commercial rights for alvelestat.

• On exercise of the option by Sentynl, the agreement provides funding for the global Phase 3 study, which could be initiat

2026
Q1

Q1 2026 Earnings

8-K/A SELL

May 12, 2026 · 100% conf.

AI Prediction SELL

1D

+0.38%

$0.25

Act: +5.49%

5D

-5.64%

$0.23

Act: -3.25%

20D

+6.47%

$0.26

Act: +23.86%

Price: $0.25 Prob +5D: 0% AUC: 1.000
0001193125-26-218290

EX-99.1

2 mreo-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Highlights

London, May 12, 2026 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the first quarter ended March 31, 2026, and provided an update on recent corporate developments.

“Based on extensive analysis of data across the two global Phase 3 studies of setrusumab in osteogenesis imperfecta in collaboration with our partner Ultragenyx, we believe there is basis to engage with the regulatory agencies to determine if there is a path forward in pediatric patients. These interactions have been initiated, and we plan to provide updates once we have some definitive feedback. We continue to believe that setrusumab has the potential to provide meaningful benefit for people living with OI, a condition with no FDA or EMA approved therapies,” said Denise Scots-Knight, Chief Executive Officer of Mereo. “We are actively engaged with potential partners for alvelestat in AATD-LD and believe alvelestat can quickly enter Phase 3 development following closing of a partnership transaction. Our other partnered program, vantictumab, is continuing to move forward with āshibio, who plan to initiate a Phase 2 trial in osteopetrosis in the second half of 2026. We continue to expect that our cash position, which totaled $36.2 million as of March 31, will provide runway into mid-2027, through several key inflection points expected during the remainder of this year.”

Recent Corporate Developments and Anticipated Milestones

Setrusumab (UX143)

• Further analyses of the data from the Orbit and Cosmic Phase 3 studies, including patient subgroups, have been completed.

• While neither study achieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates (Cosmic), both studies achieved high statistical significance against the key secondary endpoint of improvement in bone mineral density versus control as well as reductions in vertebral fractures and improvements in patient reported outcomes (PROs) associated with disease severity, pain / discomfort and daily activities, with these PRO improvements achieving statistical significance in the Orbit study.

• The safety profile of setrusumab was consistent with that observed in prior studies.

• Based on the Phase 3 data analysis from both global Phase 3 studies and the safety profile of setrusumab, Mereo and its partner Ultragenyx believe there is a basis to engage regulatory agencies to determine if there is a path forward for setrusumab in pediatric patients. These interactions have been initiated.

Alvelestat (MPH-966)

• Mereo is actively engaged in discussions with potential partners for the Phase 3 development and commercialization of alvelestat.

• Based on previous discussions with the FDA and EMA, Mereo anticipates a single Phase 3 trial enrolling approximately 220 early- and late-stage AATD-LD patients evaluating alvelestat over an 18-month treatment period will support regulatory submissions in both the U.S. and Europe.

o The primary efficacy endpoint for potential U.S. approval will be the St. George’s Respiratory Questionnaire (SGRQ) Total Score, with lung density measured by CT scan serving as the primary endpoint for potential European regulatory approval. These are independent primary endpoints.

o The Company believes initiation of the Phase 3 study could happen within 6 months of closing a potential partnership transaction.

Vantictumab (OMP18R5)

• The Company’s development partner for vantictumab, āshibio, Inc., is continuing to advance toward initiation of a Phase 2 clinical trial in autosomal dominant osteopetrosis Type 2 (ADO2), which is expected to commence in the second half of 2026.

• āshibio is responsible for funding the global clinical program and holds the right to commercialize vantictumab outside of Europe, where Mereo has retained commercial rights.

First Quarter 2026 Financial Results

Total research and development (“R&D”) expenses increased by $0.8 million, from $3.9 million in the first quarter of 2025 to $4.7 million in the first quarter of 2026. The increase was primarily due to increases of $1.8 million in R&D expenses for setrusumab, partially offset by reductions of $0.9 million in R&D expenses for alvelestat. The increase in program expenses for setrusumab was primarily driven by recognition of a payable for our share of certain costs related to the cancellation of manufacturing slots by our partner, Ultragenyx, partially offset by reductions of, and delays to, investment in manufacturing and ongoing activities, including medical affairs activities in Europe during the first quarter of 2026. The decrease in program expenses for alvelestat was primarily due to completion of activit

Share on Social Networks: